Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
about
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agentsComparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsNKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity.Small-Molecule Carbohydrate-Based Immunostimulants.Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.New Directions for Natural Killer T Cells in the Immunotherapy of Cancer.Program Cell Death Receptor-1-Mediated Invariant Natural Killer T-Cell Control of Peritoneal Macrophage Modulates Survival in Neonatal Sepsis.Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens.Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants.Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia
P2860
Q26748456-890653A0-2756-46C7-BE56-955B717E102BQ36191001-A655FE74-6DDB-4F02-96BA-4CFA6B4E50EBQ38412832-16C95581-CCA6-44E7-9E50-C86AF266C549Q38844616-54992823-CF9B-4F95-B54D-71B0033F44A0Q39049093-C5719CF3-960B-40B4-B79C-0C49C8D65A7DQ47094180-EFE52B88-92B9-4904-A5C0-6DE0880B13C1Q47160878-6E0DA78B-CA42-4714-BF67-12A024502C3DQ50075685-3F14A3A6-32F4-47AC-97F0-A63FE9D9C2F9Q50531631-F4EC8084-2802-4DD8-88E0-639D6DF33600Q52394368-AD0CCB56-D950-4C94-ACCA-ED17589D6018Q58799058-ACA160EF-C9B8-4218-BF20-AF0DA3F89B9E
P2860
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@ast
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@en
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@nl
type
label
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@ast
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@en
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@nl
prefLabel
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@ast
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@en
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@nl
P2093
P2860
P1433
P1476
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
@en
P2093
Albert Bendelac
Bernard Orlandini
Haylene Nell
Josianne Nitcheu Tefit
Luc Teyton
Paul B Savage
Sandrine Crabé
Shenglou Deng
Vincent Serra
P2860
P304
P356
10.1016/J.VACCINE.2014.08.070
P407
P577
2014-09-13T00:00:00Z